Company / Cost of Revenue
Arcadia Biosciences, Inc. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$3.0M
FY2025
5-year range
$2.2M / $8.7M
FY2021-FY2025
Trend
+36.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue returned to growth in FY2025 after 2 years of decline, reaching $3M.
Based on SEC 10-K filings.
$3M in FY2025 with a 3-year CAGR of -30.2%.
Improved from $6M to $3M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -30.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -30.2%, indicating a declining trend.
- In FY2025, cost of revenue increased 36.3% year-over-year.
- Peak cost of revenue was recorded in FY2022.
- Lowest cost of revenue in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 7.60 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.0M | +36.3% |
| FY2024 | $2.2M | -64.4% |
| FY2023 | $6.1M | -29.9% |
| FY2022 | $8.7M | +67.5% |
| FY2021 | $5.2M | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | $895.0K | +0.3% |
| FY2016 | $892.0K | -55.3% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026